News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II (World)
ProMetic Life Sciences Inc. (PFSCF.PK) To Present At The Piper Jaffray 27th Annual Healthcare Conference In New York On Tuesday December 1, 2015 11/24/2015
Qu Biologics Completes Enrollment Of Randomized Clinical Trial In Crohn's Disease 11/24/2015
F. Hoffmann-La Roche Ltd. (RHHBY) Release: Combination Of Bevacizumab And Lomustine With First Recurrence Of Glioblastoma Prolongs PFS But Not OS 11/23/2015
Generon (Shanghai) Corporation Ltd. Collaborating With Mayo Clinic To Initiate A Phase IIa Study With F-652, A First-In-Class Biologic, To Treat Patients With Alcoholic Hepatitis 11/23/2015
BioLineRx Ltd. Announces Initiation Of Phase 1/2 Trial For Novel Treatment In Two Bone Marrow Failure Conditions 11/23/2015
Poxel Presents New Data On Imeglimin And PXL770 At The World Congress On Insulin Resistance, Diabetes And Cardiovascular Diseases In Los Angeles 11/23/2015
FDA Calls Merck KGaA (MKGAF.PK), Pfizer (PFE)'s Skin Cancer Drug Avelumab a Breakthrough 11/19/2015
Immodulon Therapeutics Release: Five-year Survival In Patients With Metastatic Melanoma Receiving IMM-101 11/19/2015
DelMar Pharma Reports First Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 11/17/2015
Allergan (AGN) Release: Positive Phase I/II Interim Data Of Bimatoprost Sustained-Release Implant For IOP Therapy In Glaucoma 11/16/2015
DelMar Pharma Presents Data Summarizing The Potential Of VAL-083 As A New Treatment Option For Resistant Cancers 11/13/2015
Albireo To Present A4250 Clinical Data At The 2015 American Association for Study of Liver Diseases Annual Meeting 11/12/2015
Allergan (AGN) Presents Data At The 2015 American Academy of Ophthalmology Annual Meeting In Las Vegas 11/12/2015
NeuroDerm (NDRM) Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease 11/11/2015
GenKyoTex S.A. 's GKT137831 Granted Orphan Drug Designation In The US And EU For The Treatment Of Systemic Sclerosis 11/11/2015
AstraZeneca PLC (AZN)'s Lupus Drug Anifrolumab Meets Goals in Mid-Stage Study 11/10/2015
DelMar Pharma To Present Updated Phase II Safety And Efficacy Data On VAL-083 In Refractory Glioblastoma Multiforme 11/10/2015
Teva (TEVA) Snags Breakthrough Therapy Designation from the FDA for Huntington's Disease Drug 11/9/2015
BiondVax Pharmaceuticals Announces Third Quarter 2015 Financial Results And Update 11/9/2015
AEterna Zentaris (AEZS) Reports Third Quarter Financial And Operating Results 11/6/2015
OncoGenex (OGXI) To Present At The Stifel 2015 Healthcare Conference 11/6/2015
ESSA Pharma Receives Health Canada Approval To Commence Clinical Development For EPI-506 11/5/2015
Oncolytics Biotech Inc. (ONC.TO) Announces 2015 Third Quarter Results 11/5/2015
ProNAi Therapeutics, Inc. Reports Third Quarter 2015 Results 11/5/2015
BioLineRx Ltd. Announces Positive Clinical Results From First Part Of Phase II Trial In R/R AML 11/5/2015
DelMar Pharma To Present At The SeeThruEquity Microcap Investor Forum On November 12, 2015 11/5/2015
Verona Pharma (VRP.L) Release: Completion Of Patient Enrolment In Two RPL554 Phase IIa Studies, Ahead Of Expected Timeline 11/5/2015
Zealand Pharma  (ZEAL.CO) Is Ready To Take Next Steps In A Diligent Growth Strategy For Accelerated Value Creation: From Peptide To Patient 11/4/2015
Janssen Sciences Ireland UC Release: First Investigational All Injectable Long Acting HIV Combination Regimen Study Results At 32 Weeks Announced 11/3/2015
ViiV Healthcare Announces Positive Headline Results From A Study Of Two Drug Injectable Regimen For HIV Maintenance Therapy 11/3/2015
Invion Limited Announces Full Enrollment Of NIH-Sponsored Asthma Trial 11/2/2015
Axovant (AXON) Announces RVT-101 Presentations At The Clinical Trials In Alzheimer's Disease (CTAD) Meeting 10/29/2015
Astellas (ALPMY) Inititaties Phase 3 Registration Trial Of gilteritinib (ASP2215) In Relapsed Or Refractory Acute Myeloid Leukemia Patients 10/28/2015
Transition Therapeutics (TTH.TO) Announces Presentation Of ELND005 Phase 2/3 Clinical Study Results At Clinical Trials In Alzheimer's Disease (CTAD) Conference 10/28/2015
Cellular Biomedicine Group (CBMG) Presented Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma 10/28/2015
BioBlast Pharma (ORPN) Announces Positive Interim Results From HOPEMD Phase II Clinical Study Of Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 10/27/2015
BioBlast Pharma (ORPN)To Host Conference Call & Webcast On Tuesday, October 27 To Discuss Interim Results From HOPEMD Phase II Clinical Study Of Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 10/27/2015
Twi Biotechnology Receives Notice Of Patent Allowance In Korea For Its Lead Drug Candidate AC-201 For The Indication Of Type II Diabetes 10/27/2015
Theravance Biopharma (TBPH) And Trek Therapeutics Announce Initiation Of Phase 2a Trial Of TD-6450, An NS5A Inhibitor To Treat Hepatitis C 10/27/2015
Prima Biomed (PRR.AX) Gains Belgian Regulatory Approval To Commence A Registration Phase Ilb Study Of IMP321 10/27/2015
Living Cell Technologies Ltd. Data Shows NTCELL Treatment Has Stopped The Progression Of Parkinsons 10/27/2015
Celgene (CELG) Release: Phase II Maintenance Data From Oral Ozanimod TOUCHSTONE Study In Ulcerative Colitis Presented At UEG Week 10/26/2015
Janssen-Cilag International NV (JNJ) Receives Positive CHMP Opinion Recommending EDURANT (rilpivirine) For The Treatment Of Adolescents Aged 12 To <18 Years With HIV-1 Infection 10/26/2015
Can-Fite BioPharma (CFBI) To Participate In BIO-Europe Partnering Conference On November 2-5, 2015 In Munich, Germany 10/26/2015
Shire (SHPG) Terminates Milestone Payments to Former Lumena Shareholders After Liver Drug Fails 10/23/2015
Aprea Presents Preliminary Clinical Phase Ib/II Results In Ovarian Cancer With APR-246 – A ‘First-In-Class’ Compound Reconverting Mutant To Wild-Type P53 Protein 10/23/2015
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015
VBL Therapeutics (VBLX) Presents Positive Data On VB-111 In Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer At The ITC 2015 Conference 10/22/2015
Onxeo Announces Data Demonstrating High Patient Compliance And Acceptability Of Validive For Treatment Of Severe Oral Mucositis 10/22/2015
DelMar Pharma Announces The Completion Of Enrollment In Its Phase II Expansion Study Of VAL-083 In Refractory Glioblastoma Multiforme 10/21/2015
BiondVax Pharmaceuticals Announces Successful Recruitment Of The First Participants In A Phase Ilb Clinical Trial In Europe With Its Universal Flu Vaccine: Multimeric M-001 10/21/2015
Foamix Pharmaceuticals, Ltd. (FOMX) Announces Enrollment Of First Patient In Phase II Clinical Trial Of FMX103 In Papulopustular Rosacea 10/20/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1b Study In Advanced Pancreatic Cancer 10/20/2015
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase IIa Study To Evaluate The Effect Of Simeprevir In Combination With Odalasvir And AL-335 10/16/2015
Generex Biotechnology Corporation (GNBT) Announces Memorandum Of Understanding In Respect Of A Phase II Clinical Trial For The Antigen Express Prostate Cancer Vaccine 10/15/2015
Kuros Biosurgery AG To Present Positive kur-115 Pre Clinical Data For Interbody Spinal Fusion Treatment At The 2015 North American Spine Society 10/15/2015
RedHill Biopharma Provides Update On BEKINDA Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D 10/14/2015
Verona Pharma (VRP.L) Announces Start Of RPL554 Phase IIa Combination Study 10/14/2015
Hutchison China MediTech (Chi-Med) Release: Savolitinib Completes Enrolment For Phase II Clinical Trial In Papillary Renal Cell Carcinoma 10/13/2015
Can-Fite BioPharma (CFBI) Announces $4.8 Million Registered Direct Offering 10/13/2015
European Medicines Agency Grants Orphan Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 10/12/2015
Kuros Presents Results Of Phase IIB Study With KUR-111 At The 2015 Orthopaedic Trauma Association Annual Meeting 10/9/2015
Bionomics Limited (BNO.AX) Announces Extension Of Strategic Collaboration With Merck & Co. (MRK) For The Discovery And Development Of Novel Pain Medications 10/8/2015
BrainStorm Cell Therapeutics Inc. Announces Treatment Of Final Patient In US Multicenter Double Blinded Phase 2 ALS Trial 10/7/2015
Ascend Announces Patients With Nodular Basal Cell Carcinoma Receives First Dose Of ASN-002 In Phase 1/2a Study 10/7/2015
Invion Limited Successfully Completes Phase 2 Study Of INV102 (Nadolol) To Aid Smoking Cessation 10/5/2015
Pharmalink AB Raises SEK100m To Advance Nefecon Development As New Treatment For Kidney Disease 10/1/2015
OncoGenex (OGXI) Announces Completion Of Patient Enrollment In Borealis-2 Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer 9/30/2015
Phase II Trial Results Show Mesoblast (MSB.AX) Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure 9/30/2015
Important New Data From Teva (TEVA)'s TEV-48125 Phase IIB Migraine Program Published In Lancet Neurology In Back-To-Back Articles 9/30/2015
DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors 9/29/2015
Can-Fite BioPharma (CFBI) To Present CF101 Psoriasis Data At Late Breaking Session Of The EADV Congress In Copenhagen On October 10, 2015 9/29/2015
Viralytics Ltd (VLA.AX) Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress 9/28/2015
AEterna Zentaris (AEZS)' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint In Men With Heavily Pretreated Castration And Taxane Resistant Prostate Cancer 9/28/2015
RXi Pharmaceuticals (RXII) Granted Patent In China For Lead Clinical Candidate RXI-109 9/28/2015
Neovacs SA Initiates Phase IIb Trial Of Ifna-Kinoid For The Treatment Of Lupus 9/24/2015
Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using uniQure (QURE)'s Novel AAV5-Based Gene Therapy 9/21/2015
BioInvent (BOVNF) And The University of Pennsylvania Enhance Planned Clinical Study With BI-505 9/21/2015
FDA Grants Fast Track Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 9/17/2015
Infectious Disease Research Institute (IDRI) And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa 9/17/2015
GW Pharma (GWPH) Surges on Positive Phase II Cannabis-Based Drug Study for Schizophrenia and Some Rare Diseases 9/16/2015
Benitec (BLT.AX) Initiates A Fourth Site In Hepatitis C Clinical Trial 9/16/2015
Aquinox (AQXP) Announces Closing Of $98.0 Million Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/16/2015
Transition Therapeutics Inc. (TTH.TO) Announces Fiscal 2015 Financial Results 9/16/2015
MerLion Pharmaceuticals Pte Ltd To Present Detailed Phase 2 Data On Efficacy Of Finafloxacin In Complicated Urinary Tract Infections At International Congress Of Chemotherapy And Infection (ICC) 9/15/2015
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Phase II Clinical Results In Colorectal Cancer To Be Presented At The 2015 European Cancer Congress 9/14/2015
PharmaMar Showcases New Data For YONDELIS And PM1183 In Soft Tissue Sarcoma And Solid Tumors At ECCO 2015 9/14/2015
Sun Biomedical (ASX: SBN) Initiates Phase II Clinical Trial Of Promising Combination Therapy For Chronic Kidney Disease 9/14/2015
BioBlast Pharma (ORPN) Granted Patent From USPTO For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 9/14/2015
Amarantus Receives Orphan Drug Designation From The FDA For MANF For The Treatment Of Retinal Artery Occlusion 9/14/2015
Innapharma Fifth DSMB Meeting Of The EffiKIR Trial Recommends Continuation Without Modification 9/14/2015
TRANSGENE (ENX:TNG) Reports Financial Results For First Six Months Of 2015 9/11/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany And Pfizer (PFE) To Present Updates For Avelumab At The European Cancer Congress 2015 9/11/2015
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Data To Be Presented At European Society Of Transplantation 9/10/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce 9/9/2015
Endo Pharmaceuticals (ENDP) And BioDelivery Sciences International (BDSI) Present New Data On Investigational Product Buprenorphine Hcl Buccal Film For Chronic Pain Management 9/9/2015
RedHill Biopharma Ltd. (RDHL) Announces $2 Million National Cancer Institute Grant For YELIVA(TM) (ABC294640) Phase II Study For Multiple Myeloma 9/9/2015
Immunocore's IMCgp100 Accepted For Adaptive Pathway Pilot Programme 9/9/2015
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme At GBM2015 9/9/2015
IAVI And CureVac Partner To Accelerate Development And Testing Of AIDS Vaccine Candidates 9/9/2015
Valeant (VRX) And Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Acceptance Of NDA Submission For Oral RELISTOR 9/8/2015
Helsinn Group Signs Exclusive Agreement With Bial For Distribution And Licence Of Anamorelin In Spain, Portugal, Angola And Mozambique 9/8/2015
ORYZON Genomics Achieves Milestone In The Clinical Development Of ORY-1001 9/8/2015
TRANSGENE (ENX:TNG) Announces Final Overall Survival Data From Phase IIb TIME Trial With TG4010 Immunotherapy In Non-Small Cell Lung Cancer 9/8/2015
Hutchison China MediTech (Chi-Med) Release: Second Proof-Of-Concept Trial Of Fruquintinib Achieves Its Primary Endpoint 9/4/2015
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results And Provides Corporate Update 9/4/2015
Oramed (ORMP) To Present At The Rodman & Renshaw Global Investment Conference 9/4/2015
Chugai Pharmaceutical Co., Ltd. (Japan)'s Bispecific Antibody "ACE910" For The Treatment Of Hemophilia A Designated As A Breakthrough Therapy By The FDA 9/4/2015
Helsinn Group Signs Exclusive Agreement With Munipharma For The Distribution And Licence Of Anamorelin In Switzerland And Liechtenstein 9/3/2015
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 To Enter Phase 2 Clinical Studies In Atopic Dermatitis And Celiac Disease In US And Europe 9/3/2015
Atopix Appoints Dr Andrew Zambanini As Chief Medical Officer 9/3/2015
Can-Fite BioPharma (CFBI) To Present At Rodman & Renshaw 17th Annual Global Investment Conference On September 9, 2015 9/1/2015
Neovacs SA Receives First Regulatory Approvals For A Phase IIb Trial Of Ifna-Kinoid In Lupus 9/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Second Quarter 2015 Results 9/1/2015
MicuRx Pharmaceuticals Says Novel Antibiotic Passes China Phase II Test 9/1/2015
ERYtech Pharma Appoints Eric Soyer As Chief Financial And Chief Operating Officer 9/1/2015
Ascletis, Inc. Phase II Clinical Trial Of Its Interferon-Free HCV Regimen In Taiwan 8/31/2015
MicuRx Pharmaceuticals Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 8/31/2015
Allergan (AGN) Successfully Completes Naurex Acquisition 8/31/2015
Oncolytics Biotech Inc. (ONC.TO) Collaborators To Present Survival Data From REO 016 Study In Non-Small Cell Lung Cancer 8/27/2015
iCo Therapeutics Inc. Announces Second Quarter 2015 Financial Results 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase II Non-Small Cell Lung Cancer Study 8/26/2015
XTL Biopharmaceuticals Ltd. (XTLB) Announces Publication Of Results Of Phase 2 Study On Hcdr1 (Edratide) In Patients With Active Systemic Lupus Erythematosus (SLE) In Lupus Science & Medicine 8/26/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
DelMar Pharmaceuticals To Present At The 17th Annual Rodman & Renshaw Global Investment Conference On September 9, 2015 8/25/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
BioLineRx Ltd. Reports Second Quarter 2015 Financial Results 8/20/2015
Vernalis PLC (VNLPY.PK) Completes Investment In Its NCE Development Pipeline 8/20/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence Multiple Ascending Dose Study With Promising NMDA Receptor Antagonist 8/17/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
Invion Limited Completes Clinical Trial Of INV103 (ala-Cpn10) In Lupus Patients 8/17/2015
BioLineRx Ltd. Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment 8/17/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
BrainStorm Cell Therapeutics Inc. Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
Immunovaccine Inc. Announces Financial Results For Quarter Ended June 30, 2015 8/13/2015
BioLineRx Ltd. To Report Second Quarter 2015 Results On August 20, 2015 8/13/2015
Japan Grants Safety Clearance To Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Use In Clinical Trials 8/12/2015
Aurinia (ISA.TO) Reports Second Quarter 2015 Financial Results 8/12/2015
Portage Biotech's Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million 8/11/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
BrainStorm Cell Therapeutics Inc. Announces Completion Of Enrollment In Phase 2 Clinical Trial Of NurOwn in ALS 8/11/2015
Pluristem Therapeutics (PSTI) In Key Discussions With Europe's Adaptive Pathways Group On Phase II Protocol In Critical Limb Ischemia 8/10/2015
Cold Genesys, Inc. Secures Series B Investment 8/6/2015
Galapagos (GLPG.BR) Release: Patient Recruitment Completed In FITZROY Phase 2 Crohn's Disease Study With Filgotinib 8/6/2015
Apitope Announces Completion Of Enrolment In Phase IIA Clinical Trial Of ATX-MS-1467 In Relapsing Multiple Sclerosis 8/6/2015
Aurinia (ISA.TO) To Present At The Canaccord Genuity 35th Annual Growth Conference 8/6/2015
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis 8/5/2015
TWi Pharmaceuticals, Inc. Release: Twi Biotechnology Receives Notice Of Patent Allowance For Its Lead Drug Candidate AC-201 For The Indication Of Type II Diabetes In Europe And Russia 8/3/2015
Galapagos (GLPG.BR)' Selective JAK1 Inhibitor Filgotinib Meets Key Efficacy Endpoints, Shows ACR70 Responses Up To 39%, And Maintains Safety Profile After 24 Weeks Of Treatment In DARWIN 1 Phase 2B Study 7/30/2015
Ascendis Pharma A/S To Report Top-Line Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone And Host Conference Call On Thursday, July 30, 2015 At 9:00 A.M. Eastern Time 7/30/2015
D-Pharm Ltd. Receives Final Report For Phase 2 Clinical Study Of DP-b99 In Acute High-Risk Pancreatitis Patients 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Avraham Pharmaceuticals Ltd. Announces Successful Second Interim Results In Phase IIb Study Of Ladostigil For The Treatment Of Mild Cognitive Impairment 7/28/2015
BioLineRx Ltd. Announces Top-Line Results From Bellerophon Therapeutics (BLPH)’s PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040) 7/27/2015
AcelRx (ACRX) Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-To-Severe Post-Operative Pain In Adult Patients 7/24/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of NCI-Sponsored Phase 2 Study Of PROSTVAC In Patients With Localized Prostate Cancer 7/24/2015
Mesoblast (MSB.AX) Release: Type 2 Diabetes Trial Results Published In Diabetes Care 7/23/2015
Amarantus BioSciences, Inc. Announces First Patient Dosed In Eltoprazine Phase IIb Study For Treatment Of Parkinson's Disease Levodopa-Induced Dyskinesia 7/20/2015
DelMar Pharmaceuticals Expands GBM Clinical Trial With Fifth Clinical Trial Site Added In Denver, Colorado 7/20/2015
ERYtech Pharma Announces Positive Safety Review For ERY-ASP In Its Phase II Study In Pancreatic Cancer 7/20/2015
InnaVirVax Presents Highly Encouraging Results Of Its First Clinical Study On VAC-3S Immunotherapy For HIV 7/20/2015
Mesoblast (MSB.AX) Release: Congestive Heart Failure Phase Trial Results Published In Circulation Research 7/15/2015
Cerenis Therapeutics, Inc. Announces The Results Of The LOCATION Study 7/15/2015
Ascenion GmbH Release: New Tuberculosis Vaccine Reaches Further Clinical Development Milestone 7/15/2015
ErgoMed’s Co-Development Partner Ferrer Initiates Phase IIa Study Of Lorediplon In Patients With Insomnia 7/14/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
Independent Data Safety Monitoring Board Recommends Continuation Per Protocol Of Genticel's Phase II Clinical Trial Of GTL001 (Procervix), Company's First-In-Class HPV Therapeutic Vaccine Candidate 7/8/2015
Independent Data Safety Monitoring Board Recommends Continuation, Per Protocol, Of Genticel’s Phase 2 Clinical Trial Of GTL001 (Procervix), Company’s First-In-Class HPV Therapeutic Vaccine Candidate 7/7/2015
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Evotec AG (EVTG.F), Roche (RHHBY)'s Alzheimer's Hopeful Fails Another Trial 7/2/2015
Teva (TEVA) And Xenon Pharmaceuticals Inc. Provide Update On TV-45070 Phase IIb Study In Osteoarthritis Pain 7/1/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
Pharma Two B Ltd. Announces Positive Results In Its Phase Ilb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease 6/30/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 6/29/2015
Aquinox (AQXP)’s Bladder Pain Drug Fails to Meet Statistical Endpoint in Phase II Trial 6/25/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Alcobra (ADHD)’s Fragile X Syndrome Drug Fails During Mid-Stage Trial 6/24/2015
ObsEva Announces Recruitment Of The First Patient In TERM Phase 2 Study 6/23/2015
Vaxil BioTherapeutics's Lead Product Immucin Has Been Granted An Orphan Drug Designation By The FDA For The Treatment Of Multiple Myeloma 6/22/2015
Galapagos (GLPG.BR) Completes Recruitment For ORIGIN Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 6/18/2015
BiondVax Pharmaceuticals Announces FDA Acceptance Of IND Application For Its Investigational Universal Flu Vaccine 6/17/2015
Akaal Pharma Receives Approval To Initiate Phase II Clinical Trial For The Topical Treatment Of Psoriasis 6/16/2015
Teva (TEVA) Advances Pipeline Of Movement Disorder Assets With Announcement Of Positive Top-Line Data From The First Pivotal Study Of Investigational Treatment For Patients With Tardive Dyskinesia 6/16/2015
CTI BioPharma Release: Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
BioLineRx Ltd. Presents Positive Safety And Efficacy Results For Novel Stem-Cell Mobilization Treatment At European Hematology Association Conference 6/15/2015
Celgene (CELG) Release: Results From Analyses Of Revlimid MCL-002 (SPRINT) Study Presented At European Hematology Association 6/15/2015
NeuroDerm (NDRM) Announces Start Of A Pharmacokinetic, Head-To-Head Comparison Study Of ND0612H And Duodopa 6/11/2015
Verona Pharma (VRP.L) Release: RPL554 Phase 2a Trial Started; Headline Data Expected Q1 2016 6/11/2015
ALK-Abello A/S's Partner, MSD, Publishes Phase II Data On House Dust Mite SLIT-Tablet In Leading Allergy Journal Journal 6/10/2015
Postive Trial Results Of Mesoblast (MSB.AX) Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease 6/9/2015